Login Register Cart 0
Review Article

佛手柑精油对疼痛相关BPSDs的临床管理的神经药理学特性

卷 26, 期 20, 2019

页: [3764 - 3774] 页: 11

弟呕挨: 10.2174/0929867325666180307115546

价格: $65

conference banner
摘要

背景：阿尔茨海默氏病（AD）约占所有痴呆病例的50％，尽管在开发可改善疾病的药物方面做出了巨大努力，但尚无明确的认知障碍治疗方法。为了更好地控制该疾病，需要完全坚持目前的认知能力下降疗法，这已被证明可以减少（尽管不能完全消除）痴呆症的相关行为和心理症状（BPSD）的发生。这些症状明显影响患者的健康相关生活质量（HRQL），与疼痛状态密切相关。抗精神病药是治疗BPSD的唯一方法。但是，这些药物在短期内（6-12周）更有效，更安全，能够控制攻击性但不能控制躁动，并且无法控制疼痛。 Melissa officinalis和Lavandula officinalis的香薰疗法已被用于处理BPSD，但尚未提供强有力的证据来减轻疼痛。 目的：佛手柑精油（BEO）通过多种药理机制发挥抗伤害作用：特别是，它能够增强自噬，而自噬是在慢性疼痛中发生紊乱的过程。因此，已经指出了在BPSD的治疗中用BEO进行芳香疗法的临床翻译的良好药理基础。 结论：BEO在实验性疼痛模型中引起的抗伤害感受力使其成为与疼痛相关的BPSD的药理学治疗的可能候选者。

关键词: 香薰，佛手柑精油，老年痴呆症，痴呆症，痴呆症的行为和心理症状，疼痛。

« Previous Next »
[1]
Prince, M.W.A.; Guerchet, M.; Ali, G.C.; Wu, Y.; Prina, A.M. World Alzheimer Report 2015: The global impact of dementia. An analysis of prevalence, incidence, costs and trends; Alzheimer’s Disease International: London, 2015.
[2]
Winblad, B.; Amouyel, P.; Andrieu, S.; Ballard, C.; Brayne, C.; Brodaty, H.; Cedazo-Minguez, A.; Dubois, B.; Edvardsson, D.; Feldman, H.; Fratiglioni, L.; Frisoni, G.B.; Gauthier, S.; Georges, J.; Graff, C.; Iqbal, K.; Jessen, F.; Johansson, G.; Jönsson, L.; Kivipelto, M.; Knapp, M.; Mangialasche, F.; Melis, R.; Nordberg, A.; Rikkert, M.O.; Qiu, C.; Sakmar, T.P.; Scheltens, P.; Schneider, L.S.; Sperling, R.; Tjernberg, L.O.; Waldemar, G.; Wimo, A.; Zetterberg, H. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol., 2016, 15(5), 455-532.
[http://dx.doi.org/10.1016/S1474-4422(16)00062-4] [PMID: 26987701]
[3]
Jarvik, G.; Larson, E.B.; Goddard, K.; Schellenberg, G.D.; Wijsman, E.M. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am. J. Hum. Genet., 1996, 58(1), 191-200.
[PMID: 8554056]
[4]
Slooter, A.J.; Cruts, M.; Kalmijn, S.; Hofman, A.; Breteler, M.M.; Van Broeckhoven, C.; van Duijn, C.M. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch. Neurol., 1998, 55(7), 964-968.
[http://dx.doi.org/10.1001/archneur.55.7.964] [PMID: 9678314]
[5]
Chartier-Harlin, M.C.; Parfitt, M.; Legrain, S.; Pérez-Tur, J.; Brousseau, T.; Evans, A.; Berr, C.; Vidal, O.; Roques, P.; Gourlet, V. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet., 1994, 3(4), 569-574.
[http://dx.doi.org/10.1093/hmg/3.4.569] [PMID: 8069300]
[6]
Swaab, D.F.; Dubelaar, E.J.; Hofman, M.A.; Scherder, E.J.; van Someren, E.J.; Verwer, R.W. Brain aging and Alzheimer’s disease; use it or lose it. In: Prog. Brain Res; , 2002; 138, pp. 343-373.
[http://dx.doi.org/10.1016/S0079-6123(02)38086-5] [PMID: 12432778]
[7]
Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; O’Gorman, J.; Qian, F.; Arastu, M.; Li, M.; Chollate, S.; Brennan, M.S.; Quintero-Monzon, O.; Scannevin, R.H.; Arnold, H.M.; Engber, T.; Rhodes, K.; Ferrero, J.; Hang, Y.; Mikulskis, A.; Grimm, J.; Hock, C.; Nitsch, R.M.; Sandrock, A. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 2016, 537(7618), 50-56.
[http://dx.doi.org/10.1038/nature19323] [PMID: 27582220]
[8]
Lyketsos, C.G.; Steinberg, M.; Tschanz, J.T.; Norton, M.C.; Steffens, D.C.; Breitner, J.C. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry, 2000, 157(5), 708-714.
[http://dx.doi.org/10.1176/appi.ajp.157.5.708] [PMID: 10784462]
[9]
Ballard, C.; Corbett, A. Agitation and aggression in people with Alzheimer’s disease. Curr. Opin. Psychiatry, 2013, 26(3), 252-259.
[http://dx.doi.org/10.1097/YCO.0b013e32835f414b] [PMID: 23528917]
[10]
Margallo-Lana, M.; Swann, A.; O’Brien, J.; Fairbairn, A.; Reichelt, K.; Potkins, D.; Mynt, P.; Ballard, C. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int. J. Geriatr. Psychiatry, 2001, 16(1), 39-44.
[http://dx.doi.org/10.1002/1099-1166(200101)16:1<39:AID-GPS269>3.0.CO;2-F] [PMID: 11180484]
[11]
Kozman, M.N.; Wattis, J.; Curran, S. Pharmacological management of behavioural and psychological disturbance in dementia. Hum. Psychopharmacol., 2006, 21(1), 1-12.
[http://dx.doi.org/10.1002/hup.745] [PMID: 16389667]
[12]
Hersch, E.C.; Falzgraf, S. Management of the behavioral and psychological symptoms of dementia. Clin. Interv. Aging, 2007, 2(4), 611-621.
[http://dx.doi.org/10.1007/s11920-019-1049-5] [PMID: 18225462]
[13]
Finkel, S.I. Behavioral and psychologic symptoms of dementia. Clin. Geriatr. Med., 2003, 19(4), 799-824.
[http://dx.doi.org/10.1016/S0749-0690(03)00046-6] [PMID: 15024813]
[14]
Huang, Y.J.; Lin, C.H.; Lane, H.Y.; Tsai, G.E. NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s Disease. Curr. Neuropharmacol., 2012, 10(3), 272-285.
[http://dx.doi.org/10.2174/157015912803217288] [PMID: 23450042]
[15]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. I: Disorders of thought content. Br. J. Psychiatry, 1990, 157, 72-76, 92-94.
[http://dx.doi.org/10.1192/bjp.157.1.72] [PMID: 2397365]
[16]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. II: Disorders of perception. Br. J. Psychiatry, 1990, 157, 76-81, 92-94.
[http://dx.doi.org/10.1192/bjp.157.1.76] [PMID: 2397366]
[17]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. III: Disorders of mood. Br. J. Psychiatry, 1990, 157, 81-86, 92-94.
[http://dx.doi.org/10.1192/bjp.157.1.81] [PMID: 2397367]
[18]
Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer’s disease. IV: Disorders of behaviour. Br. J. Psychiatry, 1990, 157, 86-94.
[http://dx.doi.org/10.1192/bjp.157.1.86] [PMID: 2397368]
[19]
Tariot, P.N.; Mack, J.L.; Patterson, M.B.; Edland, S.D.; Weiner, M.F.; Fillenbaum, G.; Blazina, L.; Teri, L.; Rubin, E.; Mortimer, J.A. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer’s Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer’s Disease. Am. J. Psychiatry, 1995, 152(9), 1349-1357.
[http://dx.doi.org/10.1176/ajp.152.9.1349] [PMID: 7653692]
[20]
Harwood, D.G.; Barker, W.W.; Ownby, R.L.; Duara, R. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2000, 15(5), 393-400.
[http://dx.doi.org/10.1002/(SICI)1099-1166(200005)15:5<393:AID-GPS120>3.0.CO;2-O] [PMID: 10822237]
[21]
Savva, G.M.; Zaccai, J.; Matthews, F.E.; Davidson, J.E.; McKeith, I.; Brayne, C. Medical Research Council Cognitive Function and Ageing Study. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br. J. Psychiatry, 2009, 194(3), 212-219.
[http://dx.doi.org/10.1192/bjp.bp.108.049619] [PMID: 19252147]
[22]
Corbett, A.; Husebo, B.; Malcangio, M.; Staniland, A.; Cohen-Mansfield, J.; Aarsland, D.; Ballard, C. Assessment and treatment of pain in people with dementia. Nat. Rev. Neurol., 2012, 8(5), 264-274.
[http://dx.doi.org/10.1038/nrneurol.2012.53] [PMID: 22487749]
[23]
Zarow, C.; Lyness, S.A.; Mortimer, J.A.; Chui, H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol., 2003, 60(3), 337-341.
[http://dx.doi.org/10.1001/archneur.60.3.337] [PMID: 12633144]
[24]
Parvizi, J.; Van Hoesen, G.W.; Damasio, A. Selective pathological changes of the periaqueductal gray matter in Alzheimer’s disease. Ann. Neurol., 2000, 48(3), 344-353.
[http://dx.doi.org/10.1002/1531-8249(200009)48:3<344:AID-ANA9>3.0.CO;2-S] [PMID: 10976641]
[25]
Willis, W.D.; Westlund, K.N. Neuroanatomy of the pain system and of the pathways that modulate pain. J. Clin. Neurophysiol., 1997, 14(1), 2-31.
[http://dx.doi.org/10.1097/00004691-199701000-00002] [PMID: 9013357]
[26]
Scherder, E.J.; Sergeant, J.A.; Swaab, D.F. Pain processing in dementia and its relation to neuropathology. Lancet Neurol., 2003, 2(11), 677-686.
[http://dx.doi.org/10.1016/S1474-4422(03)00556-8] [PMID: 14572736]
[27]
Ossipov, M.H.; Dussor, G.O.; Porreca, F. Central modulation of pain. J. Clin. Invest., 2010, 120(11), 3779-3787.
[http://dx.doi.org/10.1172/JCI43766] [PMID: 21041960]
[28]
Han, J.S.; Bird, G.C.; Neugebauer, V. Enhanced group III mGluR-mediated inhibition of pain-related synaptic plasticity in the amygdala. Neuropharmacology, 2004, 46(7), 918-926.
[http://dx.doi.org/10.1016/j.neuropharm.2004.01.006] [PMID: 15081788]
[29]
Li, W.; Neugebauer, V. Differential roles of mGluR1 and mGluR5 in brief and prolonged nociceptive processing in central amygdala neurons. J. Neurophysiol., 2004, 91(1), 13-24.
[http://dx.doi.org/10.1152/jn.00485.2003] [PMID: 13679408]
[30]
Bourgeais, L.; Gauriau, C.; Bernard, J.F. Projections from the nociceptive area of the central nucleus of the amygdala to the forebrain: a PHA-L study in the rat. Eur. J. Neurosci., 2001, 14(2), 229-255.
[http://dx.doi.org/10.1046/j.0953-816x.2001.01640.x] [PMID: 11553276]
[31]
Husebo, B.S.; Strand, L.I.; Moe-Nilssen, R.; Husebo, S.B.; Ljunggren, A.E. Pain in older persons with severe dementia. Psychometric properties of the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) pain scale in a clinical setting. Scand. J. Caring Sci., 2010, 24(2), 380-391.
[http://dx.doi.org/10.1111/j.1471-6712.2009.00710.x] [PMID: 20210897]
[32]
Ballard, C.; Howard, R. Neuroleptic drugs in dementia: benefits and harm. Nat. Rev. Neurosci., 2006, 7(6), 492-500.
[http://dx.doi.org/10.1038/nrn1926] [PMID: 16715057]
[33]
Schneider, L.S.; Dagerman, K.; Insel, P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry, 2006, 14(3), 191-210.
[http://dx.doi.org/10.1097/01.JGP.0000200589.01396.6d] [PMID: 16505124]
[34]
Ballard, C.G.; Gauthier, S.; Cummings, J.L.; Brodaty, H.; Grossberg, G.T.; Robert, P.; Lyketsos, C.G. Management of agitation and aggression associated with Alzheimer disease. Nat. Rev. Neurol., 2009, 5(5), 245-255.
[http://dx.doi.org/10.1038/nrneurol.2009.39] [PMID: 19488082]
[35]
Scuteri, D.; Morrone, L.A.; Rombola, L.; Avato, P.R.; Bilia, A.R.; Corasaniti, M.T.; Sakurada, S.; Sakurada, T.; Bagetta, G. Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Clinical Evidence and Possible Mechanisms. Evid. Based Complement. Alternat. Med., 2017, 2017, 9416305.
[http://dx.doi.org/10.1155/2017/9416305] [PMID: 28465709]
[36]
Husebo, B.S.; Ballard, C.; Sandvik, R.; Nilsen, O.B.; Aarsland, D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ, 2011, 343, d4065.
[http://dx.doi.org/10.1136/bmj.d4065] [PMID: 21765198]
[37]
Morrone, L.A.; Scuteri, D.; Rombolà, L.; Mizoguchi, H.; Bagetta, G. Opioids resistance in chronic pain management. Curr. Neuropharmacol., 2017, 15(3), 444-456.
[http://dx.doi.org/10.2174/1570159X14666161101092822] [PMID: 28503117]
[38]
Jimbo, D.; Kimura, Y.; Taniguchi, M.; Inoue, M.; Urakami, K. Effect of aromatherapy on patients with Alzheimer's disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2009, 9(4), 173-9.
[http://dx.doi.org/10.1111/j.1479-8301.2009.00299.x]
[39]
Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., 1991, 82(4), 239-259.
[http://dx.doi.org/10.1007/BF00308809] [PMID: 1759558]
[40]
Gold, G.; Bouras, C.; Kövari, E.; Canuto, A.; Glaría, B.G.; Malky, A.; Hof, P.R.; Michel, J.P.; Giannakopoulos, P. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol., 2000, 99(5), 579-582.
[http://dx.doi.org/10.1007/s004010051163] [PMID: 10805104]
[41]
Carnat, A.P.; Carnat, A.; Fraisse, D.; Lamaison, J.L. The aromatic and polyphenolic composition of lemon balm (Melissa Officinalis L. subsp. Officinalis) tea. Pharm. Acta Helv., 1998, 72, 301-305.
[http://dx.doi.org/10.1016/S0031-6865(97)00026-5]
[42]
Perry, E.K.; Pickering, A.T.; Wang, W.W.; Houghton, P.; Perry, N.S. Medicinal plants and Alzheimer’s disease: integrating ethnobotanical and contemporary scientific evidence. J. Altern. Complement. Med., 1998, 4(4), 419-428.
[http://dx.doi.org/10.1089/acm.1998.4.419] [PMID: 9884179]
[43]
Perry, E.K.; Pickering, A.T.; Wang, W.W.; Houghton, P.J.; Perry, N.S. Medicinal plants and Alzheimer’s disease: from ethnobotany to phytotherapy. J. Pharm. Pharmacol., 1999, 51(5), 527-534.
[http://dx.doi.org/10.1211/0022357991772808] [PMID: 10411211]
[44]
Wake, G.; Court, J.; Pickering, A.; Lewis, R.; Wilkins, R.; Perry, E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J. Ethnopharmacol., 2000, 69(2), 105-114.
[http://dx.doi.org/10.1016/S0378-8741(99)00113-0] [PMID: 10687867]
[45]
Kennedy, D. O.; Wake, G.; Savelev, S.; Tildesley, N. T.; Perry, E. K.; Wesnes, K. A.; Scholey, A. B. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, 28(10), 1871-81.
[46]
Dastmalchi, K.; Ollilainen, V.; Lackman, P.; Boije af Gennäs, G.; Dorman, H.J.; Järvinen, P.P.; Yli-Kauhaluoma, J.; Hiltunen, R. Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorg. Med. Chem., 2009, 17(2), 867-871.
[http://dx.doi.org/10.1016/j.bmc.2008.11.034] [PMID: 19070498]
[47]
Berliocchi, L.; Russo, R.; Maiarù, M.; Levato, A.; Bagetta, G.; Corasaniti, M.T. Autophagy impairment in a mouse model of neuropathic pain. Mol. Pain, 2011, 7, 83.
[http://dx.doi.org/10.1186/1744-8069-7-83] [PMID: 22023914]
[48]
Yu, W.H.; Cuervo, A.M.; Kumar, A.; Peterhoff, C.M.; Schmidt, S.D.; Lee, J.H.; Mohan, P.S.; Mercken, M.; Farmery, M.R.; Tjernberg, L.O.; Jiang, Y.; Duff, K.; Uchiyama, Y.; Näslund, J.; Mathews, P.M.; Cataldo, A.M.; Nixon, R.A. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J. Cell Biol., 2005, 171(1), 87-98.
[http://dx.doi.org/10.1083/jcb.200505082] [PMID: 16203860]
[49]
Berliocchi, L.; Maiarù, M.; Varano, G.P.; Russo, R.; Corasaniti, M.T.; Bagetta, G.; Tassorelli, C. Spinal autophagy is differently modulated in distinct mouse models of neuropathic pain. Mol. Pain, 2015, 11, 3.
[http://dx.doi.org/10.1186/1744-8069-11-3] [PMID: 25645145]
[50]
Russo, R.; Cassiano, M.G.; Ciociaro, A.; Adornetto, A.; Varano, G.P.; Chiappini, C.; Berliocchi, L.; Tassorelli, C.; Bagetta, G.; Corasaniti, M.T. Role of D-Limonene in autophagy induced by bergamot essential oil in SH-SY5Y neuroblastoma cells. PLoS One, 2014, 9(11), e113682.
[http://dx.doi.org/10.1371/journal.pone.0113682] [PMID: 25419658]
[51]
Bagetta, G.; Morrone, L.A.; Rombolà, L.; Amantea, D.; Russo, R.; Berliocchi, L.; Sakurada, S.; Sakurada, T.; Rotiroti, D.; Corasaniti, M.T. Neuropharmacology of the essential oil of bergamot. Fitoterapia, 2010, 81(6), 453-461.
[http://dx.doi.org/10.1016/j.fitote.2010.01.013] [PMID: 20093169]
[52]
Kuwahata, H.; Komatsu, T.; Katsuyama, S.; Corasaniti, M.T.; Bagetta, G.; Sakurada, S.; Sakurada, T.; Takahama, K. Peripherally injected linalool and bergamot essential oil attenuate mechanical allodynia via inhibiting spinal ERK phosphorylation. Pharmacol. Biochem. Behav., 2013, 103(4), 735-741.
[http://dx.doi.org/10.1016/j.pbb.2012.11.003] [PMID: 23159543]
[53]
Farmacopea Ufficiale Italiana. In: Droghe Vegetali e Preparazioni (IX Edizione); Istituto Poligrafico e Zecca dello Stato, 1991; p. 75.
[54]
Corasaniti, M.T.; Maiuolo, J.; Maida, S.; Fratto, V.; Navarra, M.; Russo, R.; Amantea, D.; Morrone, L.A.; Bagetta, G. Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro. Br. J. Pharmacol., 2007, 151(4), 518-529.
[http://dx.doi.org/10.1038/sj.bjp.0707237] [PMID: 17401440]
[55]
Sakurada, T.; Mizoguchi, H.; Kuwahata, H.; Katsuyama, S.; Komatsu, T.; Morrone, L.A.; Corasaniti, M.T.; Bagetta, G.; Sakurada, S. Intraplantar injection of bergamot essential oil induces peripheral antinociception mediated by opioid mechanism. Pharmacol. Biochem. Behav., 2011, 97(3), 436-443.
[http://dx.doi.org/10.1016/j.pbb.2010.09.020] [PMID: 20932858]
[56]
Kim, S.H.; Chung, J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 1992, 50(3), 355-363.
[http://dx.doi.org/10.1016/0304-3959(92)90041-9] [PMID: 1333581]
[57]
Malmberg, A.B.; Basbaum, A.I. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain, 1998, 76(1-2), 215-222.
[http://dx.doi.org/10.1016/S0304-3959(98)00045-1] [PMID: 9696476]
[58]
Katsuyama, S.; Otowa, A.; Kamio, S.; Sato, K.; Yagi, T.; Kishikawa, Y.; Komatsu, T.; Bagetta, G.; Sakurada, T.; Nakamura, H. Effect of plantar subcutaneous administration of bergamot essential oil and linalool on formalin-induced nociceptive behavior in mice. Biomed. Res., 2015, 36(1), 47-54.
[http://dx.doi.org/10.2220/biomedres.36.47] [PMID: 25749150]
[59]
Abbadie, C.; Taylor, B.K.; Peterson, M.A.; Basbaum, A.I. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain, 1997, 69(1-2), 101-110.
[http://dx.doi.org/10.1016/S0304-3959(96)03285-X] [PMID: 9060019]
[60]
Abram, S.E.; Yaksh, T.L. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. Anesthesiology, 1994, 80(2), 383-391.
[http://dx.doi.org/10.1097/00000542-199402000-00018] [PMID: 8311320]
[61]
Ji, R.R.; Baba, H.; Brenner, G.J.; Woolf, C.J. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat. Neurosci., 1999, 2(12), 1114-1119.
[http://dx.doi.org/10.1038/16040] [PMID: 10570489]
[62]
Rombolà, L.; Corasaniti, M.T.; Rotiroti, D.; Tassorelli, C.; Sakurada, S.; Bagetta, G.; Morrone, L.A. Effects of systemic administration of the essential oil of bergamot (BEO) on gross behaviour and EEG power spectra recorded from the rat hippocampus and cerebral cortex. Funct. Neurol., 2009, 24(2), 107-112.
[PMID: 19775539]
[63]
Morrone, L.A.; Rombolà, L.; Pelle, C.; Corasaniti, M.T.; Zappettini, S.; Paudice, P.; Bonanno, G.; Bagetta, G. The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippocampus of rat: implication of monoterpene hydrocarbons. Pharmacol. Res., 2007, 55(4), 255-262.
[http://dx.doi.org/10.1016/j.phrs.2006.11.010] [PMID: 17196823]
[64]
Attwell, D.; Barbour, B.; Szatkowski, M. Nonvesicular release of neurotransmitter. Neuron, 1993, 11(3), 401-407.
[http://dx.doi.org/10.1016/0896-6273(93)90145-H] [PMID: 8104430]
[65]
Levi, G.; Raiteri, M. Carrier-mediated release of neurotransmitters. Trends Neurosci., 1993, 16(10), 415-419.
[http://dx.doi.org/10.1016/0166-2236(93)90010-J] [PMID: 7504357]
[66]
Manns, I.D.; Alonso, A.; Jones, B.E. Rhythmically discharging basal forebrain units comprise cholinergic, GABAergic, and putative glutamatergic cells. J. Neurophysiol., 2003, 89(2), 1057-1066.
[http://dx.doi.org/10.1152/jn.00938.2002] [PMID: 12574480]
[67]
Boddeke, H.W.; Best, R.; Boeijinga, P.H. Synchronous 20 Hz rhythmic activity in hippocampal networks induced by activation of metabotropic glutamate receptors in vitro. Neuroscience, 1997, 76(3), 653-658.
[PMID: 9135039]
[68]
Pittaluga, A. Presynaptic release-regulating mglu1 receptors in central nervous system. Front. Pharmacol., 2016, 7, 295.
[http://dx.doi.org/10.3389/fphar.2016.00295] [PMID: 27630571]
[69]
(WHO), W. H. O., Dementia: A Public Health Priority; WHO: Geneva, 2012.
[70]
Achterberg, W.P.; Pieper, M.J.; van Dalen-Kok, A.H.; de Waal, M.W.; Husebo, B.S.; Lautenbacher, S.; Kunz, M.; Scherder, E.J.; Corbett, A. Pain management in patients with dementia. Clin. Interv. Aging, 2013, 8, 1471-1482.
[http://dx.doi.org/10.2147/CIA.S36739] [PMID: 24204133]
[71]
Fratiglioni, L.; De Ronchi, D.; Agüero-Torres, H. Worldwide prevalence and incidence of dementia. Drugs Aging, 1999, 15(5), 365-375.
[http://dx.doi.org/10.2165/00002512-199915050-00004] [PMID: 10600044]
[72]
Laurila, J.V.; Pitkala, K.H.; Strandberg, T.E.; Tilvis, R.S. Detection and documentation of dementia and delirium in acute geriatric wards. Gen. Hosp. Psychiatry, 2004, 26(1), 31-35.
[http://dx.doi.org/10.1016/j.genhosppsych.2003.08.003] [PMID: 14757300]
[73]
Sampson, E.L.; Blanchard, M.R.; Jones, L.; Tookman, A.; King, M. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br. J. Psychiatry, 2009, 195(1), 61-66.
[http://dx.doi.org/10.1192/bjp.bp.108.055335] [PMID: 19567898]
[74]
Sampson, E.L.; White, N.; Lord, K.; Leurent, B.; Vickerstaff, V.; Scott, S.; Jones, L. Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort study. Pain, 2015, 156(4), 675-683.
[http://dx.doi.org/10.1097/j.pain.0000000000000095] [PMID: 25790457]
[75]
Tosato, M.; Lukas, A.; van der Roest, H.G.; Danese, P.; Antocicco, M.; Finne-Soveri, H.; Nikolaus, T.; Landi, F.; Bernabei, R.; Onder, G. Association of pain with behavioral and psychiatric symptoms among nursing home residents with cognitive impairment: results from the SHELTER study. Pain, 2012, 153(2), 305-310.
[http://dx.doi.org/10.1016/j.pain.2011.10.007] [PMID: 22093815]
[76]
Ahn, H.; Horgas, A. The relationship between pain and disruptive behaviors in nursing home residents with dementia. BMC Geriatr., 2013, 13, 14.
[http://dx.doi.org/10.1186/1471-2318-13-14] [PMID: 23399452]
[77]
Sakurada, T.; Kuwahata, H.; Katsuyama, S.; Komatsu, T.; Morrone, L.A.; Corasaniti, M.T.; Bagetta, G.; Sakurada, S. Intraplantar injection of bergamot essential oil into the mouse hindpaw: effects on capsaicin-induced nociceptive behaviors. Int. Rev. Neurobiol., 2009, 85, 237-248.
[http://dx.doi.org/10.1016/S0074-7742(09)85018-6] [PMID: 19607974]
[78]
Chizh, B.A.; Headley, P.M. NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. Curr. Pharm. Des., 2005, 11(23), 2977-2994.
[http://dx.doi.org/10.2174/1381612054865082] [PMID: 16178757]
[79]
Eide, P.K. Wind-up and the NMDA receptor complex from a clinical perspective. Eur. J. Pain, 2000, 4(1), 5-15.
[http://dx.doi.org/10.1053/eujp.1999.0154] [PMID: 10833550]
[80]
Park, B.Y.; Park, S.H.; Kim, W.M.; Yoon, M.H.; Lee, H.G. Antinociceptive Effect of Memantine and Morphine on Vincristine-induced Peripheral Neuropathy in Rats. Korean J. Pain, 2010, 23(3), 179-185.
[http://dx.doi.org/10.3344/kjp.2010.23.3.179] [PMID: 20830263]
[81]
Chevaleyre, V.; Takahashi, K.A.; Castillo, P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci., 2006, 29, 37-76.
[http://dx.doi.org/10.1146/annurev.neuro.29.051605.112834] [PMID: 16776579]
[82]
Lau, B.K.; Vaughan, C.W. Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray. Mol. Pharmacol., 2008, 74(5), 1392-1398.
[http://dx.doi.org/10.1124/mol.108.045872] [PMID: 18678620]
[83]
Fields, H.L.; Basbaum, A.I.; Heinricher, M.M. Central nervous systems mechanisms of pain modulation. In: Textbook of Pain,; eds., M. S. A. K. M., Ed. Elsevier, Churchill Livingston, Philadelphia, PA,. , 2006; pp. 125-142.
[http://dx.doi.org/10.1016/B0-443-07287-6/50012-6]
[84]
Coggeshall, R.E.; Zhou, S.; Carlton, S.M. Opioid receptors on peripheral sensory axons. Brain Res., 1997, 764(1-2), 126-132.
[http://dx.doi.org/10.1016/S0006-8993(97)00446-0] [PMID: 9295201]
[85]
Iremonger, K.J.; Kuzmiski, J.B.; Baimoukhametova, D.V.; Bains, J.S. Dual regulation of anterograde and retrograde transmission by endocannabinoids. J. Neurosci., 2011, 31(33), 12011-12020.
[http://dx.doi.org/10.1523/JNEUROSCI.2925-11.2011] [PMID: 21849561]
[86]
Walsh, R.N.; Cummins, R.A. The Open-Field Test: a critical review. Psychol. Bull., 1976, 83(3), 482-504.
[http://dx.doi.org/10.1037/0033-2909.83.3.482] [PMID: 17582919]
[87]
Pellow, S.; Chopin, P.; File, S.E.; Briley, M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 1985, 14(3), 149-167.
[http://dx.doi.org/10.1016/0165-0270(85)90031-7] [PMID: 2864480]
[88]
Porsolt, R.D.; Bertin, A.; Jalfre, M. “Behavioural despair” in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol., 1978, 51(3), 291-294.
[http://dx.doi.org/10.1016/0014-2999(78)90414-4] [PMID: 568552]
[89]
Detke, M.J.; Lucki, I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav. Brain Res., 1996, 73(1-2), 43-46.
[http://dx.doi.org/10.1016/0166-4328(96)00067-8] [PMID: 8788475]
[90]
Rombolà, L.; Tridico, L.; Scuteri, D.; Sakurada, T.; Sakurada, S.; Mizoguchi, H.; Avato, P.; Corasaniti, M.T.; Bagetta, G.; Morrone, L.A. Bergamot Essential oil attenuates anxiety-like behaviour in rats. Molecules, 2017, 22(4), E614.
[http://dx.doi.org/10.3390/molecules22040614] [PMID: 28398260]

Rights & Permissions Print Cite
Article Metrics
55
6
1
© 2024 Bentham Science Publishers | Privacy Policy